Lookup NU author(s): Dr Mario Abinun,
Dr Andrew Gennery
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2019 Greco, Labopin, Badoglio, Veys, Furtado Silva, Abinun, Gualandi, Bornhauser, Ciceri, Saccardi, Lankester, Alexander, Gennery, Bader, Farge and Snowden.Background: This retrospective study assessed the use and long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with severe autoimmune diseases (ADs), reported to the European Society for Blood and Marrow Transplantation (EBMT) registry. Methods: Between 1997 and 2014, 128 patients received allogeneic HSCT for various hematological (n = 49) and non-hematological (n = 79) refractory ADs. The median age was 12.7 years (0.2-62.2). Donors were syngeneic for seven, matched related for 46, unrelated for 51, haploidentical for 15, and cord blood for nine patients. Results: The incidence of grades II-IV acute graft-vs.-host disease (GvHD) was 20.8% at 100 days. Cumulative incidence of chronic GvHD was 27.8% at 5-years. Non-relapse mortality (NRM) was 12.7% at 100-days. Overall survival (OS) and Progression-Free Survival (PFS) were 70.2 and 59.4% at 5-years, respectively. By multivariate analysis, age <18 years, males, and more recent year of transplant were found to be significantly associated with improved PFS. Reduced conditioning intensity was associated with a lower NRM. On a subgroup of 64 patients with detailed information a complete clinical response was obtained in 67% of patients at 1-year. Conclusions: This large EBMT survey suggests the potential of allogeneic HSCT to induce long-term disease control in a large proportion of refractory ADs, with acceptable toxicities and NRM, especially in younger patients.
Author(s): Greco R, Labopin M, Badoglio M, Veys P, Silva JMF, Abinun M, Gualandi F, Bornhauser M, Ciceri F, Saccardi R, Lankester A, Alexander T, Gennery AR, Bader P, Farge D, Snowden JA
Publication type: Article
Publication status: Published
Journal: Frontiers in Immunology
Online publication date: 04/07/2019
Acceptance date: 24/06/2019
Date deposited: 05/08/2019
ISSN (electronic): 1664-3224
Publisher: Frontiers Media S.A.
Altmetrics provided by Altmetric